Talking Points

Joo-Yong Hahn and C. Michael Gibson compare FFR with angiography-guided PCI for patients with acute myocardial infarction and multivessel disease.

Marco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet therapy.

Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.

Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.

Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.

Milind Desai and C. Michael Gibson compare the results of mavacamten for severe obstructive hypertropic cardiomyopathy with the typical treatments of surgical septal myectomy or alcohol ablation.

Justin Ezekowitz and C. Michael Gibson look at a sodium-reducing dietary intervention and its effects on patients with HF.

Shamir Mehta and C. Michael Gibson discuss how complete revascularization affects angina-related quality of life in patients with STEMI.

Tijn Jansen, Suzette Elias-Smale, and C. Michael Gibson discuss whether diltiazem improves coronary vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease.

Mark Loeb and C. Michael Gibson discuss whether the influenza vaccine can reduce adverse vascular events among patients with HF.

Gregory Lewis and C. Michael Gibson discuss how omecamtiv mecarbil affects exercise tolerance in patients with chronic HFrEF.

Javed Butler and C. Michael Gibson discuss using patiromer to manage hyperkalemia in patients with HFrEF who are taking RAAS inhibitors.

Florian Rader and C. Michael Gibson look at cumulative outcomes for patients with obstructive hypertrophic cardiomyopathy treated with mavacamten.

Manesh Patel and C. Michael Gibson discuss the results of a phase II trial comparing the safety profiles of asundexian versus apixaban in patients with atrial fibrillation.

Daniel Sessler and C. Michael Gibson compare myocardial injury rates following mild hypothermia versus aggressive warming during noncardiac surgery.

Duk-Woo Park and C. Michael Gibson discuss edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after TAVI.

Bon-Kwon Koo and C. Michael Gibson compare the efficacy of FFR-guided and IV ultrasound-guided PCI for coronary artery stenosis.

Marie-Sophie de Koning and C. Michael Gibson discuss whether the use of sodium thiosulfate after STEMI helps preserve cardiac function.

Felix Mahfoud and C. Michael Gibson examine the efficacy of renal denervation for long-term BP reduction in patients taking antihypertensive medication.

Paul Ridker and C. Michael Gibson discuss a secondary analysis from CANTOS looking at residual inflammatory and cholesterol risks based on chronic kidney disease status.

Michael Mack and C. Michael Gibson discuss a novel method for extracting antithrombotics from the blood during CABG.

C. Michael Gibson and Jesper Hastrup Svendsen discuss the use of implantable loop recorders to prevent stroke in AF.

C. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.

Episode 162: The FIGARO-DKD Trial by TCTMD

C. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.